The U.S. health regulator issued a warning letter to Medtronic Plc highlighting certain concerns related to medical device quality management at its diabetes business, the company said on December 15.
Akorn Inc. received a warning letter from the U.S. Food and Drug Administration regarding a manufacturing facility in New Jersey, the latest in a string of setbacks for the generic drugmaker, sending the company’s shares down nearly 13 percent.
